Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | OTC | P00480 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 10/20 | 0.40 |
| ▸ | NPY1R | P25929 | 6/20 | 0.40 |
| ▸ | NPY2R | P49146 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29400705 | 1.00 | DPP7 (0.41) | DPP7OTCNPY4RNPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL118624 | 1.00 | DPP7 (0.41) | DPP7OTCNPY4RNPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL7583819 | 1.00 | DPP7 (0.41) | DPP7OTCNPY4RNPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL14831575 | 1.00 | DPP7 (0.41) | DPP7OTCNPY4RNPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL123461 | 1.00 | DPP7 (0.41) | DPP7OTCNPY4RNPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL30600460 | 0.98 | DPP7 (0.40) | DPP7OTCNPY4RNPY1RNPY2R | |
| SCHEMBL598710 | 0.98 | DPP7 (0.42) | DPP7OTCNPY4RNPY1RNPY2R | |
| SCHEMBL304115 | 0.98 | DPP7 (0.42) | DPP7OTCNPY4RNPY1RNPY2R | |
| SCHEMBL30256813 | 0.98 | DPP7 (0.42) | DPP7OTCNPY4RNPY1RNPY2R | |
| SCHEMBL5158398 | 0.98 | DPP7 (0.42) | DPP7OTCNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002098824-A2 | IMPROVEMENTS IN ENZYME STABILITY | UNISEARCH LIMITED (AU) | 2002-12-12 | — | — | WO | claimed |
| US-11512147-B2 | Hyaluronic acid derivative modified with polyethylene glycol | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-11-29 | — | — | US | disclosed |
| EP-3712181-B1 | HYALURONIC ACID DERIVATIVE MODIFIED WITH POLYETHYLENE GLYCOL | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2022-10-26 | — | — | EP | disclosed |
| US-11389539-B2 | Hyaluronic acid derivatives into which cationic and hydrophobic groups are introduced | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-07-19 | — | — | US | disclosed |
| US-20210371548-A1 | HYALURONIC ACID DERIVATIVE MODIFIED WITH POLYETHYLENE GLYCOL | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3712181-A1 | HYALURONIC ACID DERIVATIVE MODIFIED WITH POLY(ETHYLENE GLYCOL) | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-20190142959-A1 | HYALURONIC ACID DERIVATIVES INTO WHICH CATIONIC AND HYDROPHOBIC GROUPS ARE INTRODUCED | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-05-16 | — | — | US | disclosed |
| EP-3456745-A1 | HYALURONIC ACID DERIVATIVE HAVING CATIONIC GROUP AND HYDROPHOBIC GROUP INTRODUCED THEREIN | Chugai Seiyaku Kabushiki Kaisha (JP) | 2019-03-20 | — | — | EP | disclosed |
| CN-104662011-B | Treat the chroman derivative of mitochondrial disease | 康尊知识产权公司 | 2017-09-29 | — | — | CN | disclosed |
| CN-104662011-A | Chromanyl derivatives for treating mitochondrial disease | KHONDRION B V | 2015-05-27 | — | — | CN | disclosed |
| US-8389768-B2 | Methods and compositions comprising novel cationic lipids | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110117141-A1 | METHODS AND COMPOSITIONS COMPRISING NOVEL CATIONIC LIPIDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2011-05-19 | — | — | US | disclosed |
| CN-1279666-A | NPY antagonists | ASTRAZENECA AB (SE) | 2001-01-10 | — | — | CN | disclosed |
| EP-0680469-A1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | Dr. Karl Thomae GmbH (DE) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017035-A1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | DR. KARL THOMAE GMBH (DE) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117141-A1 | METHODS AND COMPOSITIONS COMPRISING NOVEL CATIONIC LIPIDS | LIPA, SGMS1, SGMS2 | DPP7 540/4885OTC 754/4885NPY4R 2769/4885 |
| US-11389539-B2 | Hyaluronic acid derivatives into which cationic and hydrophobic groups are introduced | CD44, MUC1, FUT5 | DPP7 2235/4885OTC 4121/4885NPY4R 2573/4885 |
| US-20210371548-A1 | HYALURONIC ACID DERIVATIVE MODIFIED WITH POLYETHYLENE GLYCOL | CD44, F12, HPSE | DPP7 2636/4885OTC 3904/4885NPY4R 2302/4885 |
| US-11512147-B2 | Hyaluronic acid derivative modified with polyethylene glycol | CD44, F12, HPSE | DPP7 2636/4885OTC 3904/4885NPY4R 2302/4885 |
| US-20190142959-A1 | HYALURONIC ACID DERIVATIVES INTO WHICH CATIONIC AND HYDROPHOBIC GROUPS ARE INTRODUCED | CD44, MUC1, FUT5 | DPP7 2235/4885OTC 4121/4885NPY4R 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.